T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?

Human Pathology

Volumn 39, Issue 2, 2008, Pages 194-200

  Raynaud, Pierre ^a   Caulet Maugendre, Sylvie ^b   Foussard, Charles ^c   Salles, Gilles ^d   Moreau, Anne ^e   Rossi, Jean François ^a   Patey, Martine ^e   Rousselet, Marie Christine ^c   Bene, Marie Christine ^g   Damotte, Diane ^h   Cornillet Lefebvre, Pascale ^f   Martin, Antoine ⁱ   Costes, Valérie ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HÔTEL DIEU   (France)

^f SERVICE DE DERMATOLOGIE   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

Anti CD20 monoclonal antibodies; Bcl2; Bone marrow; Follicular lymphoma; T cell infiltration

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RITUXIMAB;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FALSE POSITIVE RESULT; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA, NEOPLASM; FEMALE; GENE REARRANGEMENT; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; T-LYMPHOCYTES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 38149108954     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.05.026     Document Type: Article

References (17)

1. Douglas V., Leo G., Goolsby C., et al. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non Hodgkin lymphoma. Am J Clin Pathol 112 (1999) 844-885
2. Van Dongen J.J., Langerak A.W., Brüggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 12 (2003) 2257-2317
3. Jaffe E., Harris N.L., Stein H., and Vardiman J. World Health Organization classification of tumors: tumors of haematopoietic and lymphoid tissue (2001), IARC Press, Lyon, France
4. Uchida J., Hamaguchi Y., Oliver J.A., et al. The innate mononuclear phagocyte net work depletes B lymphocytes through Fc receptor-dependent mechanisms during anti CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
5. Weng W.K., and Levy R. Expression of complement inhibitors CD46, CD55 and CD59 on T cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98 (2001) 1352-1357
6. Byrd J.C., Kitada S., Flinn I.W., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukaemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
7. Janas E., Priest R., Wilde J.I., White J.H., and Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139 (2005) 439-446
8. Manches O., Lui G., Chaperot L., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101 (2003) 949-954
9. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
10. Kennedy G., Tey S.K., Cobcroft R., et al. Incidence and nature of CD20-negative relapse following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 119 (2002) 412-416
11. Chu P.G., Chen Y.Y., Molina A., et al. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 43 (2002) 2335-2341
12. Foran J., Norton A., Micallef I., et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol 114 (2001) 881-883
13. Dworzak M.N., Fritsch G., Printz D., et al. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 92 (1998) 3203-3209
14. Berinstein N.L., Grillo-Lopez A.J., White A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998) 995-1001
15. Chang K., Arber D., and Weiss L. CD20: a review. Appl Immunochem 4 (1999) 1-15
16. Selenko N., Majdic O., Jager U., et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J Clin Immunol 22 (2002) 124-130
17. Cartron G., Waltier H., Golay J., et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642